{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:31:32Z","timestamp":1762979492594},"reference-count":5,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,6,30]],"date-time":"2006-06-30T00:00:00Z","timestamp":1151625600000},"content-version":"vor","delay-in-days":7546,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pacing Clinical Electrophis"],"published-print":{"date-parts":[[1985,11]]},"abstract":"<jats:p>Flecainide acetate is a recently introduced, class 1 antiarrhythmic agent that is highly effective in the treatment of ventricular and atrioventricular\/ nodal reentrant tuchycardias.<jats:sup>1,2<\/jats:sup> Although both intravenous and orally administered flecainide are known to cause an increase in the pacing threshold,<jats:sup>3<\/jats:sup> an abrupt and potentially lethal rise in threshold causing failure of a properly functioning, newly implanted pacing system has not to our knowledge been described. We report such a case to stress the need for caution when using this drug in elderly pacemaker patients.<\/jats:p>","DOI":"10.1111\/j.1540-8159.1985.tb05910.x","type":"journal-article","created":{"date-parts":[[2006,7,2]],"date-time":"2006-07-02T10:03:33Z","timestamp":1151834613000},"page":"900-902","source":"Crossref","is-referenced-by-count":16,"title":["Pacing Failure Due to Flecainide Acetate"],"prefix":"10.1111","volume":"8","author":[{"given":"PAUL R.","family":"WALKER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARK","family":"PAPOUCHADO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MICHAEL A.","family":"JAMES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LEONARD M.","family":"CLARKE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,30]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.67.5.1117"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.48.2.140"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1983.tb04410.x"},{"key":"e_1_2_1_5_2","first-page":"14","volume-title":"Tambocor (flecainide acetate): Clinical and pharmacological data","year":"1983"},{"key":"e_1_2_1_6_2","first-page":"85","article-title":"Editorial: Flecainide acetate","volume":"1","year":"1984","journal-title":"Lancet"}],"container-title":["Pacing and Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8159.1985.tb05910.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8159.1985.tb05910.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T01:24:29Z","timestamp":1697765069000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8159.1985.tb05910.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,11]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1985,11]]}},"alternative-id":["10.1111\/j.1540-8159.1985.tb05910.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8159.1985.tb05910.x","archive":["Portico"],"relation":{},"ISSN":["0147-8389","1540-8159"],"issn-type":[{"value":"0147-8389","type":"print"},{"value":"1540-8159","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,11]]}}}